|
PAD4 Inhibitor Therapy for Managing Heart Failure and Diabetic Complications
PAD4 Inhibitor Therapy for Managing Heart Failure and Diabetic Complications
Background
Heart failure and diabetic complications, including cardiomyopathy and nephropathy, are significant global health challenges affecting millions. Heart failure, specifically heart failure with preserved ejection fraction (HFpEF), is characterized by impaired heart...
Published: 3/25/2026
|
Updated: 3/25/2026
|
Inventor(s):
Keywords(s):
Category(s): Technology Classifications > Invention Type > Therapeutics > Small Molecule, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Disease Area > Cardiology, Technology Classifications > Disease Area > Cardiovascular
|
|
Advancing Treatment of Hemoglobinopathies: Precision Gene-Editing and Base Editing to Restore Fetal Hemoglobin Production
Advancing Treatment of Hemoglobinopathies: Precision Gene-Editing and Base Editing to Restore Fetal Hemoglobin Production
Background
Hemoglobinopathies, such as β-thalassemias and sickle cell anemia, are genetic disorders with significant impact on global health, affecting millions with severe anemia due to abnormal or deficient β-globin....
Published: 3/24/2026
|
Updated: 3/24/2026
|
Inventor(s):
Keywords(s):
Category(s): Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Invention Type > Therapeutics > Gene Therapy, Technology Classifications > Disease Area > Hematology/Oncology, Technology Classifications > Disease Area > Hematology
|
|
Macrophage Immunomodulation by Mesenchymal Stem Cell Exosome Treatment and Restoration of Lung Architecture in Models of Bronchopulmonary Dysplasia
Macrophage Immunomodulation by Mesenchymal Stem Cell Exosome Treatment and Restoration of Lung Architecture in Models of Bronchopulmonary Dysplasia
Background
Bronchopulmonary dysplasia (BPD) is a chronic lung condition primarily affecting premature infants due to exposure to oxygen or mechanical ventilation impacting their immature lungs. BPD affects...
Published: 3/13/2026
|
Updated: 3/13/2026
|
Inventor(s):
Keywords(s):
Category(s): Technology Classifications > Disease Area > Pulmonary, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Invention Type > Therapeutics > Drug Delivery
|
|
Therapeutic Applications of Exosomes/Microvesicles from Bone Marrow Mesenchymal Cells in Pulmonary Disease
Therapeutic Applications of Exosomes/Microvesicles from Bone Marrow Mesenchymal Cells in Pulmonary Disease
Background
Premature infants face a critical risk of developing chronic lung diseases such as bronchopulmonary dysplasia (BPD), impacting about 35-40% of those born before 29 weeks of gestation. BPD alongside pulmonary hypertension (PH) results...
Published: 3/12/2026
|
Updated: 3/12/2026
|
Inventor(s): Stella Kourembanas, S. Alex Mitsialis, Konstantino Sdrimas
Keywords(s):
Category(s): Technology Classifications > Disease Area > Pulmonary, Technology Classifications > Invention Type > Therapeutics > Drug Delivery, Technology Classifications > Invention Type > Therapeutics
|
|
Targeting Gasdermin for Management of Inflammatory Diseases and Cancer
Targeting Gasdermin for Management of Inflammatory Diseases and Cancer
Background
Inflammation is a key factor in numerous diseases, including sepsis, inflammatory bowel disease, Alzheimer’s disease, and cancer. Millions worldwide are affected by these conditions, with sepsis affecting over 49 million people annually and Alzheimer’s impacting...
Published: 3/23/2026
|
Updated: 3/9/2026
|
Inventor(s):
Keywords(s):
Category(s): Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Invention Type > Therapeutics > Small Molecule, Technology Classifications > Disease Area > Immunology > Inflammation, Technology Classifications > Disease Area > Neurology, Technology Classifications > Disease Area > Neurology > Alzheimer's Disease
|
|
Novel Telomere Regulation Technology
Novel Telomere Regulation Technology
Background
Telomeres, protective caps at the ends of chromosomes, play a crucial role in maintaining cellular health. Their length is a key determinant of a cell's ability to replicate. Shortened telomeres, due to genetic mutations or acquired environmental insults, lead to telomerase dysfunction. This has...
Published: 3/23/2026
|
Updated: 12/5/2025
|
Inventor(s): Suneet Agarwal, Baris Boyraz, Neha Nagpal
Keywords(s): Aging, dyskeratosis congenita, Telomere
Category(s): Technology Classifications > Disease Area > Hematology/Oncology, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Invention Type > Therapeutics > Small Molecule, Technology Classifications > Invention Type > Therapeutics > RNA (ie. mRNA, siRNA)
|
|
Advancing Hemoglobinopathy Care: Innovative BCL11A Inhibition for Sustained Fetal Hemoglobin Production
Advancing Hemoglobinopathy Care: Innovative BCL11A Inhibition for Sustained Fetal Hemoglobin Production
Background
Hemoglobinopathies, including sickle cell anemia and β-thalassemias, are genetic disorders caused by mutations that impair the production or structure of of β-globin chains in hemoglobin. These conditions result in patients...
Published: 3/25/2026
|
Updated: 12/5/2025
|
Inventor(s): Daniel Bauer, Yuxuan Wu, Jing Zeng, Scot Wolfe, Mehmet Bolukbasi, Benjamin Roscoe, Pengpeng Liu, Luk.Kevin
Keywords(s): Sickle Cell Anemia
Category(s): Technology Classifications > Invention Type > Therapeutics > Gene Therapy, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Disease Area > Hematology/Oncology, Technology Classifications > Invention Type > Therapeutics > Gene Editing
|
|
Advancements in Botulinum Neurotoxin Engineering: Enhancing Therapeutic Efficacy and Safety through Novel Receptor-Binding and Protease Domain Modifications
Advancements in Botulinum Neurotoxin Engineering: Enhancing Therapeutic Efficacy and Safety through Novel Receptor-Binding and Protease Domain Modifications
Background
Botulinum neurotoxins (BoNT) are bacterial toxins used in medical and cosmetic applications for their ability to block neurotransmitter release, causing targeted paralysis. While BoNT/A...
Published: 3/26/2026
|
Updated: 11/29/2025
|
Inventor(s): Min Dong
Keywords(s):
Category(s): Technology Classifications > Invention Type > Therapeutics
|
|
Enhancement of extravasation and fusion factors to enable cellular therapy for Muscular dystrophies
Enhancement of extravasation and fusion factors to enable cellular therapy for Muscular dystrophies
Background
Muscular dystrophies are incurable diseases for which cell-based therapies present a promising therapeutic option. While the root cause of all muscular dystrophies is genetic, gene therapy alone cannot reverse existing muscle degeneration,...
Published: 3/23/2026
|
Updated: 11/29/2025
|
Inventor(s): Louis Kunkel, Angela Lek, Janelle Spinazzola, Yuanfan Zhang
Keywords(s):
Category(s): Technology Classifications > Invention Type > Therapeutics > Cell Therapy, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Disease Area > Genetics & Genomics
|
|
Enhanced BCL11A RNP / CRISPR delivery & editing using a 3xNLS-Cas9
Advancing Gene Therapy for Hemoglobinopathies: Enhanced CRISPR-Cas9 with Multi-NLS Integration
Background
Sickle cell disease (SCD) and β-thalassemia are severe β-globin disorders affecting millions globally, characterized by defective adult hemoglobin that fails to transport oxygen effectively, leading to significant morbidity. Existing...
Published: 3/25/2026
|
Updated: 10/13/2025
|
Inventor(s): Daniel Bauer, Pengpeng Liu, Scot Wolfe, Yuxuan Wu, Jing Zeng
Keywords(s):
Category(s): Technology Classifications > Disease Area > Hematology, Technology Classifications > Disease Area > Rare Diseases, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Invention Type > Therapeutics > Gene Editing
|